HC Wainwright Issues Pessimistic Estimate for PLX Earnings

Posted by Brenda Bartman on May 28th, 2026

Protalix BioTherapeutics, Inc. (NYSE:PLX – Free Report) – Analysts at HC Wainwright dropped their Q2 2026 earnings per share estimates for Protalix BioTherapeutics in a research note issued to investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.01 for the quarter, down from their prior estimate of $0.27. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q3 2026 earnings at $0.01 EPS and FY2026 earnings at $0.25 EPS.

Protalix BioTherapeutics Stock Performance

Protalix BioTherapeutics stock opened at $2.12 on Thursday. The stock has a 50-day moving average of $2.14 and a two-hundred day moving average of $2.20. Protalix BioTherapeutics has a one year low of $1.32 and a one year high of $3.19. The stock has a market cap of $170.81 million, a PE ratio of -16.31 and a beta of -0.01.

Institutional Investors Weigh In On Protalix BioTherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd purchased a new stake in Protalix BioTherapeutics in the fourth quarter valued at about $26,000. NewEdge Advisors LLC purchased a new stake in Protalix BioTherapeutics in the first quarter valued at about $39,000. BNP Paribas Financial Markets raised its stake in Protalix BioTherapeutics by 126.5% in the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock valued at $34,000 after buying an additional 8,498 shares during the last quarter. Virtu Financial LLC purchased a new stake in Protalix BioTherapeutics in the third quarter valued at about $37,000. Finally, SG Americas Securities LLC purchased a new stake in Protalix BioTherapeutics in the fourth quarter valued at about $31,000. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

About Protalix BioTherapeutics

(Get Free Report)

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.